{"id":"W4283326517","doi":"10.1097/01.hs9.0000843644.02496.66","title":"S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Adverse effect; Phases of clinical research; Refractory (planetary science); Clinical trial; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002742247,0.0006679558,0.00113317,0.0006153722,0.0002068705,0.001045103,0.0007749618,0.0008093482,0.004283926],"category_scores_gemma":[0.001193704,0.000246385,0.001139897,0.0006407019,0.000231561,0.0005968997,0.0003268587,0.001105095,0.001103552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007299456,"about_ca_system_score_gemma":0.001474863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00092195,"about_ca_topic_score_gemma":0.002036135,"domain_scores_codex":[0.99937,0.0002433547,0.00006554615,0.00004716657,0.0001979173,0.00007606859],"domain_scores_gemma":[0.999241,0.0001351148,0.0002937392,0.00003227175,0.0001582651,0.0001395496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07514418,0.005761216,0.01212287,0.005825459,0.003686935,0.0006439128,0.0002058519,0.002189639,0.05102475,0.0006255688,0.05355142,0.7892182],"study_design_scores_gemma":[0.1722084,0.1835825,0.1227201,0.002876655,0.01094941,0.006890804,0.0001772756,0.004311267,0.05191645,0.0008235521,0.4433688,0.0001747649],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6397173,0.2951602,0.003910506,0.007403472,0.001823251,0.004330094,0.01836904,0.000756966,0.02852917],"genre_scores_gemma":[0.7840316,0.1352261,0.01197325,0.01126854,0.002088899,0.002565295,0.04280093,0.00023347,0.00981191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004283926,"threshold_uncertainty_score":0.01450258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03588206454185491,"score_gpt":0.3080620892896637,"score_spread":0.2721800247478088,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}